Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples